Linearity [Regulatives / Guidelines]

posted by jag009  – NJ, 2022-01-24 16:06 (818 d 00:29 ago) – Posting: # 22752
Views: 2,241

Hi Ohlbe,

❝ Does your drug show linear PK ? If not: does it show more-than-proportional increase (then the highest strength would be more sensitive to show differences in BA) or less-than-proportional increase (lowest strength would be more sensitive, giving you good arguments) ?


Yes its linear PK. I read the FDA guidance about Guidance, for NDA it seeems "possible" as long as one can provide safety and efficacy data.

John

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,649 registered users;
20 visitors (0 registered, 20 guests [including 7 identified bots]).
Forum time: 17:36 CEST (Europe/Vienna)

As soon as we abandon our own reason, and are content
to rely upon authority, there is no end to our troubles.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5